POSTER SESSION V
Wednesday, March 21, 2012   —  9:30 AM - 12:00 Noon
CC Exhibit Hall B3 & C


Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...


BREAST PATHOLOGY



Poster#Title and AuthorsItinerary
Planner
12 Imaging and Pathology Discrepancies in Lymph Node Evaluation of Mammary Carcinoma (176)
M Kasami, T Uematsu, T Oichi, M Abe - Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan 		Add
13 Number of Positive Sentinel Nodes after Pre-Screening with Axillary Ultrasound Is Predictive of Overall Axillary Tumor Burden in Breast Carcinoma (294)
RJ Wolsky, CB Bills, H Sattar - University of Chicago, Chicago, IL 		Add
14 Predicting Non-Sentinel Lymph Node Status in Breast Cancer Patients with Metastases in Sentinel Lymph Nodes (209)
AJ McCarthy, K O´Connor, F O´Connell, MW Bennett, TJ Browne - Cork University Hospital, Cork, Ireland 		Add
15 Distribution Patterns of Micrometastases and Isolated Tumor Cell Clusters (ITC) in Sentinel Lymph Nodes from the NSABP B-32 Trial (219)
SR Nankoe, JM Skelly, T Ashikaga, SP Harlow, DN Krag, DL Weaver - University of Vermont College of Medicine, Burlington, VT 		Add
16 Combined Approach for Staging the Axilla Versus Sentinel Lymph Node Alone – A Cost Effective Approach Limiting the Extent of Axillary Dissections in Breast Cancer Patients (235)
EA Pirruccello, PC McGrath, VV Krol, RK Patel, RL Stewart, YM Brill, AL Szabunio, LM Samayoa - University of Kentucky, Lexington, KY; VAMC, Lexington, KY 		Add
17 A Single Institution Analysis of Metastatic Breast Carcinoma and Axillary Sentinel Lymph Node False-Negative Intraoperative Interpretations over a Ten Year Period (306)
D Yu, S Silverman, J Danyluk - Misericordia Hospital, Edmonton, AB, Canada; University of Alberta, Edmonton, AB, Canada 		Add
18 Impact of ACOSOG Trial Results in the Practice of Breast Cancer Surgery in Long Island: Survey of 19 Hospitals (228)
D Pandya, J Liu, M Singh, P Kane, C Tornos - Stony Brook University Medical Center, Stony Brook, NY 		Add
19 Preoperative Identification of N1a Disease in Clinically Node Negative Breast Cancer Patients (273)
RL Stewart, PC McGrath, H Wright, AL Szabunio, EA Pirruccello, YM Brill, VV Krol, RK Patel, LM Samayoa - University of Kentucky, Lexington, KY; Lexington VA Medical Center, Lexington, KY 		Add
20 How Many Tumor Cells in the Intraoperative Imprint Cytology of Sentinel Lymph Nodes Are Enough To Diagnose Metastatic Breast Carcinomas? (297)
M-L Wu, S-C Yang, W-C Hsieh, H-T Wang, M-H Huang, S-L Ciou, A-Y Chuang - Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan 		Add
21 Applying the American College of Surgeons Oncology Group Z0011 Trial; Can Histological Parameters Predict Axillary Nodal Understaging in Breast Carcinomas ? (223)
KM O´Connor, AJ McCarthy, F O´Connell, TJ Browne, MW Bennett - Cork University Hospital, Cork City, Ireland 		Add
22 Cytokeratin Positive Cells in Sentinel Lymph Nodes of pT1a Breast Cancers (168)
S Jaffer, C Nagi, A Nayak, R Guarino, IJ Bleiweiss - The Mount Sinai Medical Center, New York, NY 		Add
23 Axillary Recurrence after Negative Sentinel Lymph Node Dissection in Three Elderly Triple Negative Breast Cancer Patients (265)
M Sharma, KA Skinner, DG Hicks, P Tang - University of Rochester Medical Center, Rochester, NY 		Add
24 Axillary Recurrence of Breast Carcinoma (167)
S Jaffer, C Nagi, A Nayak, R Guarino, IJ Bleiweiss - The Mount Sinai Medical Center, New York, NY 		Add
25 Controversies Generated by Complete Axillary Dissections Prompted by (+) Ultrasound Guided Fine Needle Aspiration Biopsy in Clinically Node (-) Breast Cancer Patients (186)
VV Krol, EA Pirruccello, JJ Krol, PC McGrath, RK Patel, RL Stewart, AL Szabunio, YM Brill, LM Samayoa - University of Kentucky, Lexington, KY; VAMC, Lexington, KY 		Add
26 Peptide Receptors as Targets for PET/SPECT Radiopharmaceuticals: A Breast Cancer Tissue Microarray Study (283)
G Turashvili, O Goktepe, S McKinney, S Aparicio, B Guerin, F Benard - BC Cancer Research Centre, Vancouver, BC, Canada; Queen´s University and Kingston General Hospital, Kingston, ON, Canada; Université de Sherbrooke, Sherbrooke, QC, Canada 		Add
27 Is Routine Testing for Hormone Receptors Necessary in the Clinical Management of Grade 1 Breast Carcinomas? (267)
WA Shen, CJ Sung, C Zhang, MM Steinhoff, M Lomme, RA Simon, S Ehdaivand, WD Lawrence, MR Quddus - Brown University/Women & Infants Hospital, Providence, RI; Chi Mei Hospital, Liouying, Tainan, Taiwan 		Add
28 Cytokeratin 5/6 Negative Atypical Ductal Hyperplasia Predicts Disease Progression in Subsequent Breast Biopsies (221)
JC Nguyen, F Hasteh, GY Lin, N Weidner - The University of California San Diego, San Diego, CA; Clarient, Inc., Aliso Viejo, CA 		Add
29 Prediction of Prognosis in Breast Cancer by Using CD34 Immunostain and Quantitative Image Analysis (227)
U Ozerdem, EM Wojcik, GA Barkan, X Duan, C Ersahin - Loyola University Medical Center, Chicago, IL 		Add
30 Differential Expression of Milk Fat Globule-EGF Factor 8 (MFG-E8) in Breast Cancers (145)
Y Fang, Q Xie, H Wang, C Yang, AS Braverman, CA Axiotis - SUNY Downstate Medical Center/Kings County Hospital, Brooklyn, NY; BIDMC, Boston, MA; MGH, Boston, MA; SUNY Downstate Medical Canter/Kings County Hospital, Brooklyn, NY 		Add
31 Insulin-Like Growth Factor Receptor in Breast Cancer (211)
LA McLendon, C Cohen, S Patel, R Diaz, S Schmechel, A Adams, GM Oprea-Ilies - Emory University, Atlanta, GA; University of Minnesota, Minneapolis, MN 		Add
32 Tumor-Associated Macrophages and Tumor-Infiltrating CD8+ Lymphocytes in Breast Cancer: Its Association with Epithlelial-Mesenchymal Transition and Breast Cancer Stem Cell Phenotype (111)
Y Choi, DI Kim, EJ Kim, SY Park - Seoul National University Hospital, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Seoul National University College of Medicine, Seoul, Republic of Korea 		Add
33 Immunohistochemical Expression of ID4 in Triple Negative Breast Cancer Correlates with Basal Phenotype and Poorer Disease Free Survival (280)
PH Tan, AA Thike, MMM Thu, M Daniels, PY Cheok - Singapore General Hospital, Singapore 		Add
34 Variation in Assessment of ER and PR Expression of the Same Tumor Block with Repeated IHC Stainings by Computer Assisted Imaging Analysis and Manual Analysis (107)
H Chen, J Wang, L McMahon, Q Yang, H Bu, DG Hicks, P Tang - University of Rochester Medical Center, Rochester, NY; RTI Health Solution, Research Triangle Park, NC; West China Hospital of Sichuan University, Chengdu, Sichuan, China 		Add
35 Glycolytic Phenotype is Correlated with Aggressiveness and Worse Prognosis in Invasive Ductal Carcinomas (162)
H Han, SM Jang, K-S Jang, YJ Jun, YN Oh, MS Chung, SS Paik - College of Medicine, Hanyang University, Seoul, Korea 		Add
36 COX-2 (Cyclooxygenase-2) Expression Is Associated with Agressive Disease in Invasive Mammary Carcinoma (199)
K Linos, C Sheehan, J Ross - Memorial Sloan-Kettering Cancer Center, New York, NY; Albany Medical College, Albany, NY 		Add
37 Significance of Tumor CD24 and Stromal CD10 Expression in Triple Negative Breast Cancer (285)
S Varghese, N Lill, C Shapiro, WJ Zhao - Ohio State University Medical Center, Columbus, OH 		Add
38 GATA-3 Expression in Male and Female Breast Cancers: Comparison of Clinicopathologic Parameters and Outcome (159)
RS Gonzalez, J Wang, H Sullivan, A Adams, C Cohen - Emory University, Atlanta, GA 		Add
39 Immunophenotype Profile of Breast Carcinoma Brain Metastases in Comparison to Their Breast Primaries (256)
RS Saad, A El-sayed, A Shehata, M Mashhour, W Hanna - Sunnybrook Health Sciences Centre, Toronto, Canada 		Add
40 Type 2 3a/Type 5 17b-HSD (AKR1C3) Is a Negative Regulator of Breast Cancer Proliferation: An Immunohistochemical and In Vitro Study (217)
P Murugan, H-K Lin, W Wu, V Miller, Q Yang, K-M Fung - University of Oklahoma Health Sciences Center, Oklahoma City 		Add
41 Cytokeratin Immunohistochemical Profile of Breast Cancer: Do CK7 Negative Breast Carcinomas Exist? (141)
E Elishaev, R Bhargava - Magee Women´s Hospital of UPMC, Pittsburgh, PA 		Add
42 Cytoplasmic Beta-Catenin Expression Associated with Triple Negative and HER2 Positive Breast Cancer Subtypes in African-American Women (144)
AK Esnakula, LJ Ricks-Santi, YM Kannan, TJ Naab - Howard University Hospital, Washington, DC; Howard University Cancer Center, Washington, DC 		Add
43 Sphingosine Kinase Type 1 (SPHK-1) and Sphingosine- 1-Phosphate Receptor 1 (S1PR1/EDG1) Positive Breast Carcinomas Are Associated with Increased Incidence of Distant Metastases (248)
HT Richard, JP Bergeron, JA Almenara, MO Idowu - Virginia Commonwealth University, Richmond, VA 		Add
44 Changing Frequency of Equivocal HER2/Neu Scores and Factors Predictive of Negative HER2/Neu Fluorescent In-Situ Hybridization in Invasive Carcinomas of the Breast (100)
FI Boulos, CJ Youssef Massad, FA Fedda, CG Farra, EM Saad Aldin, H Doumiati, AN Tawil, A Tfayli - American University of Beirut Medical Center, Beirut, Lebanon 		Add
45 Effect of Normal Gand Staining on Amplification Results by FISH in HER2/Neu 3+ Invasive Carcinoma of the Breast (147)
FA Fedda, CG Farra, AN Tawil, A Tfayli, FI Boulos - American University of Beirut Medical Center, Beirut, Lebanon 		Add
46 The Use of Tumor Heterogeneity Scoring in Determining the Amount of Tissue Required for HER2 Diagnosis in Breast Cancer (239)
SJ Potts, H Lange, DG Young, N Landis, DA Eberhard - Flagship Biosciences, Flagstaff, AZ; University of North Carolina, Chapel Hill, NC 		Add
47 CEP17 ´Polysomy´ (CEP17P): Definition and Impact on HER2 Copy Number (CN) in Breast Carcinoma (90)
K Astvatsaturyan, J Mirocha, S Bose - Cedars-Sinai Medical Center, Los Angeles, CA 		Add
48 Utilization of Dual ISH and RT-PCR Enhances Resolution of IHC and FISH Double Equivocal Testing Results in Breast Carcinoma (237)
BP Portier, Z Wang, E Mincae, C Lanigan, E Downs-Kelly, R Tubbs - Cleveland Clinic, Cleveland, OH 		Add
49 Utilization of Oligo-Array CGH To Determine HER2 Amplification Status, Amplicon Genomic Span, and Co- Amplification Signatures: Potential Complementary Role to HER2 FISH Testing (238)
BP Portier, Z Wang, C Lanigan, G Batiouchko, E Downs-Kelly, T Richmond, D Gerhardt, K Munn, W Haagmans, R Tubbs - Cleveland Clinic, Cleveland, OH; Roche NimbleGen, Inc., Madison, WI 		Add
50 Resolving Equivocal HER2 Status in Breast Cancer by Automated and Quantitative RNA Chromogenic In Situ Hybridization (CISH) (288)
Z Wang, S Bui, H Wang, N Su, X-J Ma, Y Luo, RR Tubbs - Cleveland Clinic, Cleveland, OH; Advanced Cell Diagnostics, Hayward, CA 		Add
51 HER2/Neu Gene Amplification Heterogeneity: The Significance of Cells with a 3:1 HER2/CEP17 Ratio (191)
LJ Layfield, R Schmidt - University of Utah School of Medicine, Salt Lake City, UT; ARUP Laboratories, Salt Lake City, UT 		Add
52 Clinical Role of Total Osteopontin and Osteopontin-c mRNA in Subtypes of Breast Carcinoma (226)
F Ortiz-Martinez, FJ Gutierrez-Avino, D Giner, D Ciprian, L Andres, E Adrover, FI Aranda, E Lerma, G Peiro - Hospital General Universitari, Alacant, Spain; Hospital de Cruces, Barakaldo, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain 		Add
53 Sonic Hedgehog (Shh) and Patched-1 (PTCH1) Protein Expression in Invasive Mammary Carcinoma; (PTCH1) Protein Expression Independently Predicts Outcome (156)
J Garbaini, K-A Kim, C Sheehan, A Boguniewicz, J Ross - Albany Medical College, Albany, NY 		Add
54 Polycomb Genes and Large Non Coding RNAs Expressions in Invasive Breast Carcinomas: New Clues for Epigenetic Targeted Therapies (212)
D Meseure, K Drak Alsibai, M Trassard, R Lidereau, I Bieche - Institut Curie, St Cloud, France 		Add
55 Claudin-Low Breast Cancer; a Molecular Subtype Associated with Poor Prognosis (131)
K Dias, S Parpia, G Pond, MN Levine, T Whelan, AL Bane - McMaster Univeristy, Hamilton, ON, Canada; McMaster University, Hamilton, ON, Canada 		Add
56 Metabolomic Transmethylation Profiling Reveals Differences in ER- Compared to ER+ Breast Cancer in African-American Women (143)
AK Esnakula, TJ Naab, LJ Ricks-Santi, S Dasi, H Paul, RL DeWitty, W Frederick, E Gabrielson, YM Kannan - Howard University Hospital, Washington, DC; Johns Hopkins University, Baltimore, MD 		Add
57 Dichotomy Effects of Akt Signal on Breast Epithelia by Inhibiting Epithelial-Mesenchymal Transition, Motility, and Stem Cell, but Sustaining Survival (266)
R Shen, Z Peng, W Zhou, JR Scott, JR Chao, K-Y Teng, MWY Chan, H-JL Lin - The Ohio State University, Columbus, OH; University of Arizona, Phoenix, AZ; National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan 		Add
58 RNA Binding Protein IMP3 Is Helpful in Differentiating Borderline and Malignant Phyllodes Tumor of the Breast (302)
X Yang, B Ustun, S Goodman, D Kandil, A Khan - UMassMemorial Medical Center, Worcester, MA 		Add
59 FGFR1 Amplification in Breast Cancers with Unfavorable Features (233)
K Pfaltz, S Schneider, S Eppenberger-Castori, C Tapia - University Bern, Bern, Switzerland; University Hospital Basel, Basel, Switzerland 		Add
60 Chromosome 17 Polysomy and Monosomy as Predictive Markers of Complete Pathological Response (pCR) in Women with Locally Advanced Breast Cancer (LABC) (139)
L Elavathil, P Nirmalanantham, B Dhesy, G Gohla, O Boutross-Tadross, J Ramsay, T Aziz, A Bane, S Tang, A Lytwyn - Juravinski Hospital, Hamilton, ON, Canada; Juravinski Cancer Centre, Hamilton, ON, Canada 		Add
61 Long Non-Coding RNA and Polycomb Protein Expression Levels Are Increased in Metastatic Versus Primary Breast Carcinoma (110)
KM Chisholm, R Li, Y Wan, H Chang, RB West - Stanford University School of Medicine, Stanford, CA 		Add